Módulo 2 – Curso pós-graduado – VIH e Envelhecimento

Non-AIDS Defining Cancers Among HIV Infected People

Clinical Management of non-AIDS defining cancers


  1. INSIGHT START Study Group, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373:795-807.
  2. Moltó J, Moran T, Sirera G, Clotet B. Lung cancer in HIV-infected patients in the combination antiretroviral treatment era. Transl Lung Cancer Res. 2015;4:678-88.
  3. D’Jaen GA, Pantanowitz L, Bower M, et al. Human immunodeficiency virus-associated primary lung cancer in the era of highly active antiretroviral therapy: a multi-institutional collaboration. Clin Lung Cancer. 2010;11:396-404.
  4. Sigel K, Crothers K, Gordon K, et al. CD4 measures as predictors of lung cancer risk and prognosis in HIV infection. Conference on Retroviruses and Opportunistic Infections. February 23-26, 2015, Seattle, Washington (abstract #728, accessed http://www.croiconference.org/sessions/cd4-measures-predictors-lung-cancer-risk-and-prognosis-hiv-infection , 12/feb/2016)
  5. Makinson A, Eymard-Duvernay S, Raffi F, et al. Feasibility and efficacy of early lung cancer diagnosis with chest computed tomography in HIV-infected smok- ers. AIDS. 2016;30:573-82.
  6. Okosun J, Warbey V, Shaw K, et al. Interim fluoro-2-deoxy-D-glucose-PET pre- dicts response and progression-free survival in patients with Hodgkin lympho- ma and HIV infection. AIDS. 2012;26:861-5.
  7. Uldrick TS, Little RF. How I treat classical Hodgkin lymphoma in patients infect- ed with human immunodeficiency virus. Blood. 2015;125:1226-35.
  8. Richel O, Van Der Zee RP, Smit C, De Vries HJ, Prins JM. Brief Report: Anal cancer in the HIV-positive population: slowly declining incidence after a decade of cART. J Acquir Immune Defic Syndr. 2015;69:602-5.
  9. Sendagorta E, Herranz P, Guadalajara H, Zamora FX. [Early detection of anal intraepithelial neoplasia in high-risk patients]. Actas Dermosifiliogr. 2011;102:757-65.
  10. Delhorme JB, Antoni D, Mak KS, et al. Treatment that follows guidelines closely dramatically improves overall survival of patients with anal canal and margin cancers. Crit Rev Oncol Hematol. 2016;101:131-8.
  11. Spano JP, Poizot-Martin I, Costagliola D, et al. Non-AIDS-related malignancies: expert consensus review and practical applications from the multidisciplinary CANCERVIH Working Group. Ann Oncol. 2016;27:397-408.
  12. Gramenzi A, Tedeschi S, Cantarini MC, et al. Outcome of hepatocellular carcinoma in human immunodeficiency virus-infected patients. Dig Liver Dis. 2013;45:516-22.
  13. Yopp AC, Subramanian M, Jain MK, et al. Presentation, treatment, and clinical outcomes of patients with hepatocellular carcinoma, with and without human immunodeficiency virus infection. Clin Gastroenterol Hepatol. 2012;10:1284-90.
Logo MSD Termos de utilização | Política de Privacidade | Sobre a MSD Copyright © 2018 Todos os direitos reservados. Merck Sharp & Dohme Corp.,uma subsidiária da Merck & Co., Inc. Kenilworth, NJ, USA, conhecida fora dos EUA e Canadá como MSD. Os conteúdos disponibilizados nesta página Web são informação de carácter geral e não substituem em nenhum caso as consultas, tratamentos ou as recomendações do seu médico. INFC-1273571-0000 11/2018